Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | GLS | O94925 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15724908 | 0.87 | SMN1; SMN2 (0.72) | SMN1; SMN2GLSLMNAKDM4EUSP2 | |
| SCHEMBL21443522 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2GLSLMNAKDM4EUSP2 | |
| SCHEMBL21443551 | 0.75 | GLS (0.55) | SMN1; SMN2GLSLMNAKDM4EUSP2 | |
| SCHEMBL21443394 | 0.74 | GLS (0.74) | SMN1; SMN2GLSLMNAKDM4EUSP2 | |
| SCHEMBL17193290 | 0.72 | GLS (0.65) | SMN1; SMN2GLSLMNAKDM4EUSP2 | |
| SCHEMBL21443388 | 0.72 | SMN1; SMN2 (0.69) | SMN1; SMN2GLSLMNAKDM4EUSP2 | |
| SCHEMBL15724894 | 0.71 | GLS (0.76) | GLS | |
| SCHEMBL14987311 | 0.71 | GLS (1.00) | SMN1; SMN2GLS | |
| SCHEMBL15724909 | 0.70 | RAB9A (0.67) | SMN1; SMN2GLSLMNAHSD17B10POLB | |
| SCHEMBL17655082 | 0.70 | GLS (0.80) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922832-B1 | GLUTAMINASE INHIBITORS AND METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |